SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences in March:
TD Cowen 45th Annual Health Care Conference
Presenting on Monday, March 3, 2025, at 9:10 a.m. ET
Leerink Partners Global Biopharma Conference
Presenting on Tuesday, March 11, 2025, at 9:20 a.m. ET
Barclays 27th Annual Global Healthcare Conference
Wednesday, March 12, 2025
Jefferies Biotech on the Beach Summit
Wednesday, March 12, 2025
Live webcasts of the TD Cowen 45th Annual Health Care Conference and Leerink Partners Global Biopharma Conference presentations will be accessible on the Investor page of Travere’s website at www.ir.travere.com/events-presentations. Replays will be available for up to 30 days following each event.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
Contact:
Last Trade: | US$19.26 |
Daily Change: | 0.13 0.68 |
Daily Volume: | 168,933 |
Market Cap: | US$1.680B |
February 11, 2025 January 06, 2025 November 25, 2024 November 12, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load